Some of these side effects can be managed with palliative therapy, but others may require dose adjustments, temporary or permanent discontinuation of treatment. Rash: Nevirapine commonly causes a skin rash, though in some patients it can cause hepatitis and a life-threatening hypersensitivity reaction (see below).In developed countries, about 17% of the patients appear to develop a rash on nevirapine. The rash can be severe leading about 6-8% of patients to stop treatment.f treatment is interrupted for more than a week, restart with the lead-in dosing protocol (with one 200mg nevirapine tablet daily for the first 14 days in combination with AZT/3TC). If treatment was interrupted because of nevirapine-related side effects, watch for any signs of toxicity during lead-in treatment.